Cantor upgrades Capricor to Overweight, lifts target to $28
Cantor Fitzgerald upgrades Capricor Therapeutics to Overweight from Neutral and raises its price target to $28 from $3.50 after the Q2 call centered on the negative FDA panel vote for deramiocel.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.